The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


Great paper on a new microRNA program that stimulates cardiac regeneration from collaborative work between King's College and Maastricht University.

Myocardial regeneration is restricted to early postnatal life, when mammalian cardiomyocytes still retain the ability to proliferate. The molecular cues that induce cell cycle arrest of neonatal cardiomyocytes towards terminally differentiated adult heart muscle cells remain obscure. In this 2021 paper it is reported that the miR-106b∼25 cluster is higher expressed in the early postnatal myocardium and decreases in expression towards adulthood, especially under conditions of overload, and orchestrates the transition of cardiomyocyte hyperplasia towards cell cycle arrest and hypertrophy by virtue of its targetome.


HFA Winter Meeting 2021 Abstract published in European Journal of Heart Failure

All abstracts of previous Heart Failure Association Winter Research Meeting (January 2021) are now published in the European Journal of Heart Failure:


Patient engagement in scientific research

The European Society of Cardiology and Harteraad, both partners in the TRAIN-HEART network, focus on the close involvement of patients in cardiovascular research.


A British Heart Foundation - King's College London Centre Technology Workshop with Professor Mauro Giacca

Presenter: Professor Mauro Giacca

Title: High throughput screening


King's College publishes on RNAemia and proteome biomarker risk stratification in intensive care unit patients with COVID-19

In this paper, the group of Prof. Mayr at King’s College London assessed RNAemia, antibody response against SARS-CoV-2 and proteomic profiles in serial blood samples from COVID-19 patients admitted to two Intensive Care Units.